Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ABIVAX
  6. Company
    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo ABIVAX
ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Number of employees : 27 people.
Managers
Name Title Age Since
Hartmut J. Ehrlich, Dr. Chief Executive Officer - 2013
Didier Blondel Chief Financial Officer & Secretary - 2017
Didier Scherrer, Dr. Vice President-Research & Development - -
Paul Gineste Vice President-Clinical Operations - 2015
Sophie Biguenet, Dr. Chief Medical Officer - 2021
Joy A. Amundson Independent Director 65 -
Carol L. Brosgart, Dr. Independent Director 68 2018
Pierre Courteille Chief Commercial Officer & VP-Business Development - -
Bernard Fanget VP-Process Development & Regulatory Affairs - -
Alexandra Pearce, Dr. Vice President & Head-Regulatory Affairs - 2018
Members of the board
Name Title Age Since
Philippe Pouletty, Dr. Chairman 61 2013
Joy A. Amundson Independent Director 65 -
Jean-Jacques Bertrand Director 82 2014
Christian Pierret, Dr. Director - 2018
Antonino Ligresti, Dr. Director 81 2015
Corinna Zur Bonsen-Thomas Director - -
Carol L. Brosgart, Dr. Independent Director 68 2018
Kinam Hong, Dr. Director - -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 14,320,271 10,259,481 71.6% 12,800 0.1% 71.6%
Shareholders
NameEquities%
Truffle Capital SAS 5,505,563 38.2%
Sofinnova Partners SAS 1,698,723 11.8%
DNCA Finance SA 292,206 2.03%
LSP Advisory BV 121,926 0.85%
Sycomore Asset Management SA 79,332 0.55%
Argenta Banque d'Epargne SA 69,887 0.48%
Aramea Asset Management AG 47,000 0.33%
Candriam Belgium SA 47,000 0.33%
Etoile Gestion SA 24,861 0.17%
Banca Ifigest SpA (Investment Management) 24,000 0.17%
Holdings
NameEquities%Valuation
ABIVAX (ABVX) 12,800 0.089% 448,555 USD
Markets and indexes
- PEA / SRD eligible : YES / YES
- Compartiment B
- CAC Small / CAC All Shares, CAC All-Tradable, CAC Mid Small, CAC PME, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  ABVX.PA
- Datastream Code :  
Company contact information
ABIVAX
5 Rue de la Baume
FR-75008 Paris

Phone : +33 (0)1 53 83 08 41
Fax :
web site : https://www.abivax.com/investors/
Brand Portfolio
In partnership withAllbrands.markets
More brands of ABIVAX
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
ABIVAX-12.65%595
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 907
CUREVAC N.V.-39.24%21 497
ALNYLAM PHARMACEUTICALS, INC.37.68%21 034
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.62.86%20 449
PHARMARON BEIJING CO., LTD.64.43%20 226
ICON PUBLIC LIMITED COMPANY24.77%19 385
BIO-TECHNE CORPORATION51.86%18 755
HANGZHOU TIGERMED CONSULTING CO., LTD-2.48%18 276
INCYTE CORPORATION-11.01%17 011
PPD, INC.34.78%16 203
NOVAVAX, INC.60.82%13 285
QIAGEN N.V.-0.11%12 050
PRA HEALTH SCIENCES, INC.0.00%10 965
INTELLIA THERAPEUTICS, INC.160.75%10 305
BACHEM HOLDING AG51.71%9 267
SYNEOS HEALTH, INC.31.62%9 265